关于 NewEast Biosciences
武汉费斯德生物科技有限公司是美国NewEast Biosciences在中国的办事处。NewEast Biosciences 在十二年前率先研发俩种独特的抗体。这俩种抗体仅仅识别活性的GTP酶或者突变的Oncogene。 GTP酶涉及(1)响应细胞表面受体激活的信号转导,包括跨膜受体,例如介导味觉、嗅觉和视觉的那些,(2)核糖体的蛋白质生物合成,(3)调节细胞分化、增殖、分裂和运动,(4)蛋白质通过膜的易位,(5)细胞内囊泡的运输,以及囊泡介导的分泌和摄取,通过GTP酶控制囊泡外壳组装。Oncogene侧是诱发癌症的基因。
我公司将向你提供以下的独一无二的三种抗体或者试剂盒: (1) 仅识别 GTP酶的活性构型的产品, 它可以让你能够量化GTP酶在细胞中的活性和分布。(2) 识别突变 Oncogene蛋白, 但不认识相应野生型的抗体。 (3) 对 cAMP 和 cGMP 具有超亲和力(无需乙酰化)ELISA检测试剂盒。这些产品被将近一千篇同行评议的文章所引用。

¥4,800.00
| 货号: 26191 |
| 基因符号: H-Ras; K-Ras; N-Ras |
| 描述: HRAS(G13A) 小鼠单克隆抗体 |
| 背景: Belongs to the small GTPase superfamily. Ras family binds GDP/GTP and possess intrinsic GTPase activity, alternate between an inactive form bound to GDP and an active form bound to GTP. Activated by a guanine nucleotide-exchange factor (GEF) and inactivated by a GTPase-activating protein (GAP).Located in cell membrane, lipid-anchor, cytoplasmic side and Golgi apparatus membrane. |
| 免疫原: A synthetic peptide from the internal region of HRas which includes the mutation of G13A, human origin. |
| 经过测试的应用: ELISA, WB, IHC |
| 推荐稀释度: ELISA: 1:1000-1:5000 WB: 1:500-1:1000 IHC: 1:50-1:100 |
| 浓度: 1 mg/ml |
| 种属反应性: Mouse |
| 形式: Liquid |
| 克隆性: Monoclonal |
| 亚型: IgG |
| 纯化:: Purified from ascites |
| Preservative: No |
| 成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 50% glycerol |
| 种属反应性: Recognizes G13A mutant, but not wild type H-RAS of vertebrates. |
| 储存条件:: Store at -20°C. Avoid repeated freezing and thawing |
Western blot:
Western blot analysis of recombinant HRAS(G13A) and wild type proteins.
Purified His-tagged HRAS(G13A) protein (lane 2) and corresponding wild type protein (lane 1) were blotted with HRAS(G13A) monoclonal antibody (货号26191).
Immunofluorescence:
Immunofluorescence of cells expressing Ras proteins with HRAS(G13A) antibody. HEK293T cells were transfected with pCDNA3-GFP-HRas (WT) plasmid (left column) or pCDNA3-GFP-HRAS(G13A) plasmid (right column), then fixed and stained with HRAS(G13A) monoclonal antibody (货号26191). |
| 1. DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model Gene Therapy 21, 888-896 (October 2014) |
| 2. Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma J Clin Pathol. 2015 Aug;68(8):657-60. doi: 10.1136 |